POINT Screen Failure Log
(version 4)

Hub: | Spoke: | Month/Year:

Please list the patients who were actively screened (in person or via telephone) for the POINT study by your study team but NOT RANDOMIZED at your site.
Enter this data into WebDCU™ by the 10th day of the following month.

Any screen failures to report? 0 No 0 Yes

Screen ID # This number is assigned by WebDCU™ at the time of data entry.	A. Screening day (dd)	B. Gender 1=Female 2=Male 8=Unknown	C. Race 1=American Indian/Alaska Native 2= Asian 3= Black/African American 4= Native Hawaiian/Other Pacific Islander 5= White/Caucasian 6= Other 8= Unknown/Not reported	D. Ethnicity 1= Hispanic/ Latino 2= Not Hispanic/ Latino 8=Unknown/Not reported	E. Age (years)	H. Time of symptom onset to time of ED or clinic arrival (hours)	F. Enter primary reason patient is not enrolled in POINT (See Code List Below)	G. If primary reason is 'consent declined for other reason' or 'other' please specify (200 character Max)
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	
	__ __	__	__	__	__ __	__ __	__ __	

Code List:

1= TIA patient with $ABCD^2$ score < 4.
2= Minor ischemic stroke patient with NIHSS > 3.
3= Inability to randomize within 12 hours of time last known free of new ischemic symptoms
4= Head CT or MRI does not rule out hemorrhage or other pathology, such as vascular malformation, tumor, or abscess, that could explain symptoms or contraindicate therapy
5= Age < 18 years
6= Inability to tolerate aspirin at a dose of 50-325 mg/day
7= Symptoms of TIA limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo.
8= In the judgment of the treating physician, a candidate for thrombolysis, endarterectomy, or endovascular intervention.
9= Receipt of any intervenous or intra-arterial thrombolysis within 1 week prior to index event.
10= Gastrointestinal bleed or major surgery within 3 months prior to index event.
11= History of nontraumatic intracranial hemorrhage.
13= Clear indication for anticoagulation (eg, warfarin, heparin) anticipated during the study period
14= Qualifying ischemic event induced by angiography or surgery.
15= Severe non-cardiovascular comorbidity with life expectancy < 3 months.
16= Contraindication to clopidogrel or aspirin.
17= Anticipated requirement for long-term (>7 day) non-study antiplatelet drugs or NSAIDs affecting platelet function.
18= Inability to swallow medications.
19= At risk for pregnancy: premenopausal or post menopausal female within 12 months of last menses without a negative pregnancy test or not committing to adequate birth control
20= Unavailability for follow-up.
21= Inability to provide informed consent.
22= Other neurological conditions that would complicate assessment of outcomes during follow-up.
23= Ongoing treatment in another study of an investigational therapy or treatment in such a study within the last 7 days
24= Consent declined due to confidentiality issues.
25= Consent declined due to protocol too restrictive.
26= Consent declined due to protocol too time intensive.
27= Consent declined due to travel requirements.
28= Consent declined due to family advised declining.
29= Consent declined for other reason.
30= Not willing or able to discontinue prohibited concomitant medications
96= Other